Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes

References

• Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, De La Mora Jimenez E. et al. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020–14. doi:10.1056/NEJMoa1910231.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546. doi:10.1056/NEJMoa1910836.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E. et al. Nivolumab versus Docetaxel in advanced squamous-cell non–small-Cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa1348.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199. doi:10.1056/NEJMoa1406498.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov. 2017;16(4):264–272. doi:10.1038/nrd.2016.233.
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175(4):998–1013.e1020. doi:10.1016/j.cell.2018.10.038.
   PubMed Web of Science ®Google Scholar
• Han J, Duan J, Bai H, Wang Y, Wan R, Wang X, Chen S, Tian Y, Wang D, Fei K. et al. TCR repertoire diversity of peripheral PD-1+CD8+ T cells predicts clinical outcomes after immunotherapy in patients with non–small cell lung cancer. Cancer Immunol Res. 2020;8(1):146–154. doi:10.1158/2326-6066.CIR-19-0398.
   PubMed Web of Science ®Google Scholar
• Kidman J, Principe N, Watson M, Lassmann T, Holt RA, Nowak AK, Lesterhuis WJ, Lake RA, Chee J. Characteristics of TCR repertoire associated with successful immune checkpoint therapy responses. Front Immunol. 2020;11:11(2668. doi:10.3389/fimmu.2020.587014.
   Web of Science ®Google Scholar
• Freeman JD, Warren RL, Webb JR, Nelson BH, Holt RA. Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res. 2009;19(10):1817–1824. doi:10.1101/gr.092924.109.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/nature13954.
   PubMed Web of Science ®Google Scholar
• Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH. et al. Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell. 2017;171(4):934–949.e916. doi:10.1016/j.cell.2017.09.028.
   PubMed Web of Science ®Google Scholar
• Roh W, Chen P-L, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9(379):eaah3560. doi:10.1126/scitranslmed.aah3560.
   PubMed Web of Science ®Google Scholar
• Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI Insight. 2018;3(13). doi:10.1172/jci.insight.122092.
   Web of Science ®Google Scholar
• Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, Perez S, Plantier N, Mouret J-F, Nguyen-Kim TDL. et al. Peripheral blood TCR repertoire profiling May facilitate patient stratification for immunotherapy against Melanoma. Cancer Immunol Res. 2019;7(1):77–85. doi:10.1158/2326-6066.CIR-18-0136.
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–1986. doi:10.1056/NEJMoa1716078.
   PubMed Web of Science ®Google Scholar
• Glanville J, Huang H, Nau A, Hatton O, Wagar LE, Rubelt F, Ji X, Han A, Krams SM, Pettus C. et al. Identifying specificity groups in the T cell receptor repertoire. Nature. 2017;547(7661):94–98. doi:10.1038/nature22976.
   PubMed Web of Science ®Google Scholar
• Dash P, Fiore-Gartland AJ, Hertz T, Wang GC, Sharma S, Souquette A, Crawford JC, Clemens EB, Nguyen THO, Kedzierska K. et al. Quantifiable predictive features define epitope-specific T cell receptor repertoires. Nature. 2017;547(7661):89–93. doi:10.1038/nature22383.
   PubMed Web of Science ®Google Scholar
• Zemek RM, De Jong E, Chin WL, Schuster IS, Fear VS, Casey TH, Forbes C, Dart SJ, Leslie C, Zaitouny A. et al. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Sci Transl Med. 2019;11(501):eaav7816. doi:10.1126/scitranslmed.aav7816.
   PubMed Web of Science ®Google Scholar
• Zemek RM, Fear VS, Forbes C, De Jong E, Casey TH, Boon L, Lassmann T, Bosco A, Millward MJ, Nowak AK. et al. Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. Nat Protoc. 2020;15(5):1628–1648. doi:10.1038/s41596-020-0299-3.
   PubMed Web of Science ®Google Scholar
• Marzo AL, Lake RA, Robinson BWS, Scott B. T-Cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 1999;59:1071–1079.
   PubMed Web of Science ®Google Scholar
• Fear VS, Tilsed C, Chee J, Forbes CA, Casey T, Solin JN, Lansley SM, Lesterhuis WJ, Dick IM, Nowak AK. et al. Combination immune checkpoint blockade as an effective therapy for mesothelioma. OncoImmunology. 2018;7(10):e1494111. doi:10.1080/2162402X.2018.1494111.
   PubMed Web of Science ®Google Scholar
• Principe N, Kidman J, Goh S, Tilsed CM, Fisher SA, Fear VS, Forbes CA, Zemek RM, Chopra A, Watson M. et al. Tumor infiltrating effector memory antigen-specific CD8+ T cells predict response to immune checkpoint therapy. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.584423.
   PubMed Web of Science ®Google Scholar
• Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, Chudakov DM. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12(5):380–381. doi:10.1038/nmeth.3364.
   PubMed Web of Science ®Google Scholar
• Laydon DJ, Bangham CRM, Asquith B. Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach. Phil Trans R Soc B. 2015;370(1675):20140291. doi:10.1098/rstb.2014.0291.
   PubMed Web of Science ®Google Scholar
• Sidhom JW, Oliveira G, Ross-MacDonald P, Wind-Rotolo M, Wu CJ, Pardoll DM, Baras AS. Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. Sci Adv. 2022;8(37):eabq5089. doi:10.1126/sciadv.abq5089.
   PubMed Web of Science ®Google Scholar
• Sidhom J-W, Larman HB, Pardoll DM, Baras AS. DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires. Nat Commun. 2021;12(1). doi:10.1038/s41467-021-21879-w.
   Web of Science ®Google Scholar
• Walsh I, Fishman D, Garcia-Gasulla D, Titma T, Pollastri G, EMLF G, Harrow J, Psomopoulos FE, Tosatto SCE, Del Conte A. DOME: recommendations for supervised machine learning validation in biology. Nat Methods. 2021;18(10):1122–1127. doi:10.1038/s41592-021-01205-4.
   PubMed Web of Science ®Google Scholar
• Denisenko E, Guo BB, Jones M, Hou R, De Kock L, Lassmann T, Poppe D, Clément O, Simmons RK, Lister R. et al. Systematic assessment of tissue dissociation and storage biases in single-cell and single-nucleus RNA-seq workflows. Genome Biol. 2020;21(1). doi:10.1186/s13059-020-02048-6.
   PubMed Web of Science ®Google Scholar
• Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, Lachmann A, Wojciechowicz ML, Kropiwnicki E, Jagodnik KM. et al. Gene set knowledge discovery with Enrichr. Curr Protoc. 2021;1(3):e90. doi:10.1002/cpz1.90.
   PubMedGoogle Scholar
• Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics. 2007;23(23):3251–3253. doi:10.1093/bioinformatics/btm369.
   PubMed Web of Science ®Google Scholar
• Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E, Pawlak M, Dionne D, Xia J, Rozenblatt-Rosen O. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1−CD8+ tumor-infiltrating T cells. Immunity. 2019;50(1):181–194.e186. doi:10.1016/j.immuni.2018.11.014.
   PubMed Web of Science ®Google Scholar
• Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, Lafleur MW, Yates KB, Lako A, Felt K, Naik GS. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326–336. doi:10.1038/s41590-019-0312-6.
   PubMed Web of Science ®Google Scholar
• Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell. 2002;111(6):837–851. doi:10.1016/S0092-8674(02)01139-X.
   PubMed Web of Science ®Google Scholar
• Fairfax BP, Taylor CA, Watson RA, Nassiri I, Danielli S, Fang H, Mahé EA, Cooper R, Woodcock V, Traill Z. et al. Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nat Med. 2020;26(2):193–199. doi:10.1038/s41591-019-0734-6.
   PubMed Web of Science ®Google Scholar
• Watson RA, Tong O, Cooper R, Taylor CA, Sharma PK, de Los Aires AV, Mahé EA, Ruffieux H, Nassiri I, Middleton MR. et al. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8(+) T cell clone size and cytotoxicity. Sci Immunol. 2021;6(64):eabj8825. doi:10.1126/sciimmunol.abj8825.
   PubMed Web of Science ®Google Scholar
• Valpione S, Galvani E, Tweedy J, Mundra PA, Banyard A, Middlehurst P, Barry J, Mills S, Salih Z, Weightman J. et al. Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer. 2020;1(2):210–221. doi:10.1038/s43018-019-0022-x.
   PubMedGoogle Scholar
• Morgan DJ, Liblau R, Scott B, Fleck S, McDevitt HO, Sarvetnick N, Lo D, Sherman LA. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol. 1996;157(3):978–983. doi:10.4049/jimmunol.157.3.978.
   PubMed Web of Science ®Google Scholar
• Zemek RM, Chin WL, Fear VS, Wylie B, Casey TH, Forbes C, Tilsed CM, Boon L, Guo BB, Bosco A. et al. Temporally restricted activation of IFNbeta signaling underlies response to immune checkpoint therapy in mice. Nat Commun. 2022;13(1):4895. doi:10.1038/s41467-022-32567-8.
   PubMed Web of Science ®Google Scholar
• Huuhtanen J, Chen L, Jokinen E, Kasanen H, Lonnberg T, Kreutzman A, Peltola K, Hernberg M, Wang C, Yee C. et al. Evolution and modulation of antigen-specific T cell responses in melanoma patients. Nat Commun. 2022;13(1):5988. doi:10.1038/s41467-022-33720-z.
   PubMed Web of Science ®Google Scholar
• Tan Z, Chiu MS, Yan CW, Man K, Chen Z. Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment. Mol Ther Oncolytics. 2021;20:373–386. doi:10.1016/j.omto.2021.01.010.
   PubMed Web of Science ®Google Scholar
• Rudqvist N-P, Pilones KA, Lhuillier C, Wennerberg E, Sidhom J-W, Emerson RO, Robins HS, Schneck J, Formenti SC, Demaria S. Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells. Cancer Immunol Res. 2018;6(2):139–150. doi:10.1158/2326-6066.CIR-17-0134.
   PubMed Web of Science ®Google Scholar
• Stringhini M, Probst P, Neri D. Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response of tissue‐resident memory T cells against the AH1 rejection antigen. Eur J Immunol. 2020;50(10):1591–1597. doi:10.1002/eji.201948433.
   PubMed Web of Science ®Google Scholar
• Hosoi A, Takeda K, Nagaoka K, Iino T, Matsushita H, Ueha S, Aoki S, Matsushima K, Kubo M, Morikawa T. et al. Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy. Sci Rep. 2018;8(1). doi:10.1038/s41598-018-19548-y.
   Google Scholar
• Zhigalova EA, Izosimova AI, Yuzhakova DV, Volchkova LN, Shagina IA, Turchaninova MA, Serebrovskaya EO, Zagaynova EV, Chudakov DM, Sharonov GV. RNA-Seq-based TCR profiling reveals persistently increased intratumoral clonality in responders to anti-PD-1 therapy. Front Oncol. 2020;10(385). doi:10.3389/fonc.2020.00385.
   PubMedGoogle Scholar
• Yusko E, Vignali M, Wilson RK, Mardis ER, Hodi FS, Horak C, Chang H, Woods DM, Robins H, Weber J. Association of tumor microenvironment T-cell repertoire and mutational load with clinical outcome after sequential checkpoint blockade in melanoma. Cancer Immunol Res. 2019;7(3):458–465. doi:10.1158/2326-6066.CIR-18-0226.
   PubMed Web of Science ®Google Scholar
• Valpione S, Mundra PA, Galvani E, Campana LG, Lorigan P, De Rosa F, Gupta A, Weightman J, Mills S, Dhomen N. et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat Commun. 2021;12(1). doi:10.1038/s41467-021-24343-x.
   Web of Science ®Google Scholar
• Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu W-J, Hanna E. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649–1654. doi:10.1038/s41591-018-0197-1.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J. et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res. 2016;4(11):959–967. doi:10.1158/2326-6066.CIR-16-0143.
   PubMed Web of Science ®Google Scholar
• Tsunoda M, Aoki H, Shimizu H, Shichino S, Matsushima K, Ueha S. Proportional tumor infiltration of T cells via circulation duplicates the T cell receptor repertoire in a bilateral tumor mouse model. Front Immunol. 2021;12:744381. doi:10.3389/fimmu.2021.744381.
   PubMed Web of Science ®Google Scholar
• Chen IX, Newcomer K, Pauken KE, Juneja VR, Naxerova K, Wu MW, Pinter M, Sen DR, Singer M, Sharpe AH. et al. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proc Natl Acad Sci USA. 2020;117(38):23684–23694. doi:10.1073/pnas.2002806117.
   PubMed Web of Science ®Google Scholar
• Ma S, Chee J, Fear VS, Forbes CA, Boon L, Dick IM, Robinson BWS, Creaney J. Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. OncoImmunology. 2020;9(1):1684714. doi:10.1080/2162402X.2019.1684714.
   PubMed Web of Science ®Google Scholar
• Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50(1):195–211.e110. doi:10.1016/j.immuni.2018.12.021.
   PubMed Web of Science ®Google Scholar
• Lee S, Zhao L, Little LD, Westin SN, Jazarei AA, Fleming ND, Zhang J, Futreal PA, Sood AK. Sood AK: distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. iScience. 2021;24(2):102053. doi:10.1016/j.isci.2021.102053.
   PubMed Web of Science ®Google Scholar